Cargando…

ALK阳性非小细胞肺癌靶向治疗研究进展

The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. The first-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors represent a significant advance in the evolution of personalized medicine for...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000407/
https://www.ncbi.nlm.nih.gov/pubmed/25539610
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.05
_version_ 1783331714283601920
collection PubMed
description The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. The first-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors represent a significant advance in the evolution of personalized medicine for NSCLC. A randomized phase Ⅲ clinical trial in which superiority of crizotinib over chemotherapy was seen in previously treated ALK-positive NSCLC patients demonstrated durable responses and well tolerance in the majority of ALK-positive NSCLC patients treated with crizotinib. However, despite the initial responses, most patients develop acquired resistance to crizotinib. Several novel therapeutic approaches targeting ALK-positive NSCLC are currently under evaluation in clinical trials, including second-generation ALK inhibitors, such as LDK378, CH5424802 (RO5424802), and AP26113, and new agents shock protein 90 inhibitors. This review aims to present the current knowledge on this fusion gene, the treatment advances, and novel drug clinical trials in ALK rearranged NSCLC.
format Online
Article
Text
id pubmed-6000407
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-60004072018-07-06 ALK阳性非小细胞肺癌靶向治疗研究进展 Zhongguo Fei Ai Za Zhi 综述 The rate of the anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) tissues is 3%-5%. The first-in-class ALK tyrosine kinase inhibitor, crizotinib, can effectively target these tumors represent a significant advance in the evolution of personalized medicine for NSCLC. A randomized phase Ⅲ clinical trial in which superiority of crizotinib over chemotherapy was seen in previously treated ALK-positive NSCLC patients demonstrated durable responses and well tolerance in the majority of ALK-positive NSCLC patients treated with crizotinib. However, despite the initial responses, most patients develop acquired resistance to crizotinib. Several novel therapeutic approaches targeting ALK-positive NSCLC are currently under evaluation in clinical trials, including second-generation ALK inhibitors, such as LDK378, CH5424802 (RO5424802), and AP26113, and new agents shock protein 90 inhibitors. This review aims to present the current knowledge on this fusion gene, the treatment advances, and novel drug clinical trials in ALK rearranged NSCLC. 中国肺癌杂志编辑部 2014-12-20 /pmc/articles/PMC6000407/ /pubmed/25539610 http://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.05 Text en 版权所有©《中国肺癌杂志》编辑部2014 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 综述
ALK阳性非小细胞肺癌靶向治疗研究进展
title ALK阳性非小细胞肺癌靶向治疗研究进展
title_full ALK阳性非小细胞肺癌靶向治疗研究进展
title_fullStr ALK阳性非小细胞肺癌靶向治疗研究进展
title_full_unstemmed ALK阳性非小细胞肺癌靶向治疗研究进展
title_short ALK阳性非小细胞肺癌靶向治疗研究进展
title_sort alk阳性非小细胞肺癌靶向治疗研究进展
topic 综述
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000407/
https://www.ncbi.nlm.nih.gov/pubmed/25539610
http://dx.doi.org/10.3779/j.issn.1009-3419.2014.12.05
work_keys_str_mv AT alkyángxìngfēixiǎoxìbāofèiáibǎxiàngzhìliáoyánjiūjìnzhǎn
AT alkyángxìngfēixiǎoxìbāofèiáibǎxiàngzhìliáoyánjiūjìnzhǎn